Choi JY, Woo SD, Lee HK, Hong HK, Je YH, Park JH, Song JY, An SH, Kang
           SK
           Division of Applied Biology and Chemistry, Seoul National University,
           Suwon, Korea.
           Arch Virol 2000;145(1):171-7

        For the potential use as recombinant vaccine, canine parvovirus (CPV)
        major capsid protein VP2 was expressed using Bombyx mori
        nucleopolyhedrovirus (BmNPV) vector. CPV VP2 gene was introduced into
        polyhedrin-based BmNPV transfer vector pBmKSK3, and recombinant virus
        BmK1-Parvo was prepared. When anti-CPV.VP2 monoclonal antibody was
        employed in immunofluorescence staining, an intense signal was observed
        within BmK1-Parvo-infected Bm5 cells but not within uninfected cells or
        cells infected with a wild-type BmNPV-K1. In hemagglutination assay, the
        expression level of VP2 were 3.2 x 10(3) HA units/ml from infected Bm5
        cells, 2.1x 10(5) HA units/larvae from infected larval fat body, and
        1.6x 10(6) HA units/ml from infected larval hemolymph. These results
        suggested that BmNPV vector system using B. mori larva as host could be
        applied to efficient mass-production of recombinant vaccines.